Lundin Law PC, a shareholder rights firm, announces a class action lawsuit against Cempra, Inc. ("Cempra" or the "Company") (Nasdaq: CEMP) concerning possible violations of federal securities laws between May 1, 2016 and November 1, 2016 inclusive (the "Class Period"). Investors who purchased or otherwise acquired shares during the Class Period should contact the firm prior to the January 3, 2017 lead plaintiff motion deadline. To participate in this class action lawsuit, click here. You can also call Brian Lundin, Esquire, of Lundin Law PC, at 888-713-1033, or e-mail him at email@example.com. No class has been certified in the above action. Until a class is certified, you are not considered represented by an attorney. You may also choose to do nothing and be an absent class member. The Complaint alleges that during the Class Period, Cempra made false and/or misleading statements and/or failed to disclose that its drug solithromycin posed significant safety risks for hepatotoxicity, so the Company's public statements were materially false and misleading at all relevant times. On November 2, 2016, the U.S. Food and Drug Administration posted a preliminary review on its website of solithromycin, highlighting a significant safety signal for hepatotoxicity. Lundin Law PC was founded by Brian Lundin, a securities litigator based in Los Angeles dedicated to upholding shareholders' rights. This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.